Logo image of NXGL

NEXGEL INC (NXGL) Stock Fundamental Analysis

USA - NASDAQ:NXGL - US65344E1073 - Common Stock

2.36 USD
-0.17 (-6.72%)
Last: 10/16/2025, 8:05:44 PM
2.35 USD
-0.01 (-0.42%)
After Hours: 10/16/2025, 8:05:44 PM
Fundamental Rating

3

Taking everything into account, NXGL scores 3 out of 10 in our fundamental rating. NXGL was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NXGL have multiple concerns. NXGL is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXGL has reported negative net income.
In the past year NXGL has reported a negative cash flow from operations.
In the past 5 years NXGL always reported negative net income.
NXGL had a negative operating cash flow in each of the past 5 years.
NXGL Yearly Net Income VS EBIT VS OCF VS FCFNXGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.07%, NXGL is in line with its industry, outperforming 43.98% of the companies in the same industry.
Looking at the Return On Equity, with a value of -62.51%, NXGL is in line with its industry, outperforming 47.12% of the companies in the same industry.
Industry RankSector Rank
ROA -30.07%
ROE -62.51%
ROIC N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
NXGL Yearly ROA, ROE, ROICNXGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

NXGL's Gross Margin of 38.62% is on the low side compared to the rest of the industry. NXGL is outperformed by 67.54% of its industry peers.
In the last couple of years the Gross Margin of NXGL has grown nicely.
The Profit Margin and Operating Margin are not available for NXGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
NXGL Yearly Profit, Operating, Gross MarginsNXGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

NXGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NXGL has been increased compared to 1 year ago.
NXGL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NXGL is higher compared to a year ago.
NXGL Yearly Shares OutstandingNXGL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NXGL Yearly Total Debt VS Total AssetsNXGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of 0.02, we must say that NXGL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.02, NXGL is in line with its industry, outperforming 42.41% of the companies in the same industry.
NXGL has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
NXGL has a Debt to Equity ratio (0.17) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 0.02
ROIC/WACCN/A
WACC8.47%
NXGL Yearly LT Debt VS Equity VS FCFNXGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 1.74 indicates that NXGL should not have too much problems paying its short term obligations.
The Current ratio of NXGL (1.74) is worse than 69.63% of its industry peers.
A Quick Ratio of 0.98 indicates that NXGL may have some problems paying its short term obligations.
NXGL has a Quick ratio of 0.98. This is in the lower half of the industry: NXGL underperforms 76.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 0.98
NXGL Yearly Current Assets VS Current LiabilitesNXGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.20% over the past year.
The Revenue has grown by 133.05% in the past year. This is a very strong growth!
The Revenue has been growing by 64.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)133.05%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%100.28%

3.2 Future

Based on estimates for the next years, NXGL will show a very strong growth in Earnings Per Share. The EPS will grow by 33.27% on average per year.
NXGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.07% yearly.
EPS Next Y42.88%
EPS Next 2Y52.53%
EPS Next 3Y44.54%
EPS Next 5Y33.27%
Revenue Next Year44.56%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y38.07%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NXGL Yearly Revenue VS EstimatesNXGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
NXGL Yearly EPS VS EstimatesNXGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXGL. In the last year negative earnings were reported.
NXGL is valuated correctly with a Price/Forward Earnings ratio of 14.46.
Based on the Price/Forward Earnings ratio, NXGL is valued cheaply inside the industry as 84.82% of the companies are valued more expensively.
NXGL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.85, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 14.46
NXGL Price Earnings VS Forward Price EarningsNXGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXGL Per share dataNXGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NXGL's earnings are expected to grow with 44.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.53%
EPS Next 3Y44.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXGEL INC

NASDAQ:NXGL (10/16/2025, 8:05:44 PM)

After market: 2.35 -0.01 (-0.42%)

2.36

-0.17 (-6.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners8.81%
Inst Owner Change0%
Ins Owners14.18%
Ins Owner Change-2.77%
Market Cap19.05M
Analysts82.86
Price Target6.12 (159.32%)
Short Float %0.45%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.14%
Min EPS beat(2)-26.05%
Max EPS beat(2)11.76%
EPS beat(4)1
Avg EPS beat(4)-7.49%
Min EPS beat(4)-26.05%
Max EPS beat(4)11.76%
EPS beat(8)4
Avg EPS beat(8)-9.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-8.21%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.6%
Min Revenue beat(4)-8.21%
Max Revenue beat(4)1.24%
Revenue beat(8)4
Avg Revenue beat(8)-3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-700%
EPS NY rev (1m)0%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.46
P/S 1.63
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 6.8
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)0.16
Fwd EY6.92%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS1.45
BVpS0.58
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.07%
ROE -62.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.62%
FCFM N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
F-Score6
Asset Turnover1.2
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.73%
Cap/Sales 0.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 0.98
Altman-Z 0.02
F-Score6
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)166.83%
Cap/Depr(5y)273.19%
Cap/Sales(3y)9%
Cap/Sales(5y)18.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y42.88%
EPS Next 2Y52.53%
EPS Next 3Y44.54%
EPS Next 5Y33.27%
Revenue 1Y (TTM)133.05%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%100.28%
Revenue Next Year44.56%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y38.07%
EBIT growth 1Y18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.46%
EBIT Next 3Y50.57%
EBIT Next 5Y36.32%
FCF growth 1Y20.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.73%
OCF growth 3YN/A
OCF growth 5YN/A